Patient Identification Process Clause Samples

Patient Identification Process. During the Term, and as soon as practicable upon completion of the Strata Oncology Testing Services for a Participating Patient, Strata Oncology shall: (a) review such Full Strata Test Report to determine whether the Participating Patient has any of the Clovis Target Alterations; and (b) if such Participating Patient has any Clovis Target Alterations for which Clovis has a Clovis Trial covering the Participating Patient’s cancer indication as a Named Indication, resulting in a match to such Clovis Trial (herein, such Participating Patient referred to as an “Identified Patient”), provide to Clovis and the Identified Patient’s Provider such information in accordance with the process as described on Schedule B (such process, the “Patient Identification Process”). As between the Parties, Clovis shall be responsible for conducting the clinical eligibility screening for any Identified Patients seeking enrollment in a Clovis Trial. In addition, during the Term, Strata Oncology agrees to periodically (at least once per calendar quarter or a frequency later agreed upon by the Parties) follow-up with any Participating Study Sites that have Identified Patients, as set forth on Schedule B.